UNSPSC 51142527: Etilevodopa

This classification denotes an antiparkinsonian agent with the molecular formula C11H15NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 895X917GYE, chemically known as (-)-3,4-dihydroxy-l-phenylalanine, ethyl ester but generally known as etilevodopa, which bears US NIH Compound Identifier 170345. European Medicines Agency schedules Etilevodopa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02042MIG.

UNSPSC 51142527 Etilevodopa is a Commodity code with minimal recent state and local procurement activity directly aligned to its nominal scope. The three recent opportunities tagged to this code involve naloxone procurement, direct-to-manufacturer pharmacy initiatives, and multi-source generic pharmaceuticals and OTC products — none of which are etilevodopa-specific. The code shows a fundamental mismatch between its intended product scope and the actual work being solicited under it by state and local buyers, suggesting that either the tagging is erroneous or the code sees negligible authentic procurement volume among state and local jurisdictions.

The represented opportunities span pharmacy benefit management and pharmaceutical supply across state health agencies and county health departments. Seminole County, Florida posted an IFB on June 30, 2026 (response due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries; the Texas Health and Human Services Commission issued an RFI on April 3, 2026 seeking vendor capacity for a direct-to-manufacturer prescription program; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP on January 20, 2026 (response due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities including Oregon. Activity is concentrated in Texas and the Upper Midwest, with Florida representing the only recent county-level buyer. The absence of opportunities explicitly soliciting etilevodopa suggests this code carries little weight in current state and local procurement strategy.